Phaseline

Targets › EP300

EP300 (Histone acetyltransferase p300): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Functions as a histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. (UniProt, Q09472)

Open in Phaseline: the race on EP300, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Opna BioOPN-6602
EP300 and CBP bromodomain inhibitor
EP300, CBPPhase 1Relapsed Multiple MyelomaDec 2027
Pathos AIPocenbrodib
Selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on hi
CREBBP, EP300Phase 1mCRPC (Metastatic Castration-resistant Prostate Cancer)Jun 2028

Conditions

Relapsed Multiple Myeloma (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1)

Modalities

small molecule (2)

Companies

Opna Bio (1) Pathos AI (1)

Related targets

CBP (1) CREBBP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.